Asset Details
Do you wish to reserve the book?
Endoglin Targeting: Lessons Learned and Questions That Remain
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Endoglin Targeting: Lessons Learned and Questions That Remain
Do you wish to request the book?
Endoglin Targeting: Lessons Learned and Questions That Remain
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Endoglin Targeting: Lessons Learned and Questions That Remain
2020
Overview
Approximately 30 years ago, endoglin was identified as a transforming growth factor (TGF)-β coreceptor with a crucial role in developmental biology and tumor angiogenesis. Its selectively high expression on tumor vessels and its correlation with poor survival in cancer patients led to the exploration of endoglin as a therapeutic target for cancer. The endoglin neutralizing antibody TRC105 (Carotuximab®, Tracon Pharmaceuticals (San Diego, CA, USA) was subsequently tested in a wide variety of preclinical cancer models before being tested in phase I-III clinical studies in cancer patients as both a monotherapy and in combination with other chemotherapeutic and anti-angiogenic therapies. The combined data of these studies have revealed new insights into the role of endoglin in angiogenesis and its expression and functional role on other cells in the tumor microenvironment. In this review, we will summarize the preclinical work, clinical trials and biomarker studies of TRC105 and explore what these studies have enabled us to learn and what questions remain unanswered.
Publisher
MDPI AG,MDPI
Subject
/ Angiogenesis Inhibitors - pharmacology
/ Angiogenesis Inhibitors - therapeutic use
/ Animals
/ Antineoplastic Agents, Immunological - pharmacology
/ Antineoplastic Agents, Immunological - therapeutic use
/ Drug Evaluation, Preclinical
/ Endoglin - antagonists & inhibitors
/ Humans
/ Kinases
/ Ligands
/ Review
/ Signal Transduction - drug effects
/ Tumors
